Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Receivables (2020 - 2025)

GeneDx Holdings has reported Receivables over the past 6 years, most recently at $74.4 million for Q4 2025.

  • Quarterly results put Receivables at $74.4 million for Q4 2025, up 97.64% from a year ago — trailing twelve months through Dec 2025 was $74.4 million (up 97.64% YoY), and the annual figure for FY2025 was $74.4 million, up 97.64%.
  • Receivables for Q4 2025 was $74.4 million at GeneDx Holdings, up from $60.9 million in the prior quarter.
  • Over the last five years, Receivables for WGSWW hit a ceiling of $74.4 million in Q4 2025 and a floor of $260000.0 in Q3 2024.
  • Median Receivables over the past 5 years was $33.6 million (2021), compared with a mean of $34.2 million.
  • Biggest five-year swings in Receivables: plummeted 99.19% in 2024 and later skyrocketed 23337.69% in 2025.
  • GeneDx Holdings' Receivables stood at $26.6 million in 2021, then skyrocketed by 66.15% to $44.1 million in 2022, then decreased by 26.65% to $32.4 million in 2023, then rose by 16.24% to $37.6 million in 2024, then skyrocketed by 97.64% to $74.4 million in 2025.
  • The last three reported values for Receivables were $74.4 million (Q4 2025), $60.9 million (Q3 2025), and $48.0 million (Q2 2025) per Business Quant data.